MedTrace Logo

Sorafenib in Treating Patients With Advanced Solid Tumors

NCT00436579 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2014-02-24

No results posted yet for this study

Summary

This randomized phase I trial is studying the side effects, such as high blood pressure, and best dose of sorafenib in treating patients with advanced solid tumors. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Conditions

  • Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG

sorafenib tosylate

Given orally

OTHER

pharmacological study

PROCEDURE

assessment of therapy complications

Ancillary studies

OTHER

laboratory biomarker analysis

Correlative studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Michael Maitland · University of Chicago

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2011-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00436579 on ClinicalTrials.gov